Compare Stocks

→ With the “Bitcoin Loophole” you can supercharge the gains by 10x or more (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MXCT MaxCyte	$3.88 -1.5%	$4.35	$2.45 ▼ $5.55	$405.06M	1.34	637,436 shs	529,592 shs
ONC Oncolytics Biotech	C$1.43 -0.7%	C$1.44	C$1.20 ▼ C$4.49	C$107.85M	1.49	80,073 shs	23,151 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MXCT MaxCyte	-1.25%	-3.67%	-5.52%	-24.52%	-23.64%
ONC Oncolytics Biotech	-2.04%	-8.28%	+1.41%	-8.86%	-4.64%

AI “wealth window” is closing soon! (Ad)

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MXCT MaxCyte	1.9726 of 5 stars	3.5	2.0	0.0	0.0	0.0	2.5	0.6
ONC Oncolytics Biotech	0.5888 of 5 stars	3.5	0.0	0.0	0.0	1.1	0.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MXCT MaxCyte	3.00	Buy	$8.67	123.37% Upside
ONC Oncolytics Biotech	3.00	Buy	C$6.00	319.58% Upside

Current Analyst Ratings

Latest YGEN, BD1, MXCT, OSL, and ONC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/4/2024	ONC Oncolytics Biotech	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	C$3.00
3/13/2024	MXCT MaxCyte	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
3/13/2024	MXCT MaxCyte	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00
3/13/2024	MXCT MaxCyte	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/5/2024	MXCT MaxCyte	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MXCT MaxCyte	$41.29M	9.81	N/A	N/A	$2.23 per share	1.74
ONC Oncolytics Biotech	N/A	N/A	C$0.34 per share	4.22	C$0.37 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MXCT MaxCyte	-$37.92M	-$0.37	N/A	N/A	N/A	-91.85%	-15.90%	-13.94%	5/7/2024 (Confirmed)
ONC Oncolytics Biotech	-C$27.75M	-C$0.41	N/A	∞	N/A	N/A	-102.66%	-55.47%	5/3/2024 (Estimated)

Latest YGEN, BD1, MXCT, OSL, and ONC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2024	N/A	MXCT MaxCyte	-$0.14	N/A	+$0.14	N/A	N/A	N/A
3/12/2024	Q4 2023	MXCT MaxCyte	-$0.10	-$0.05	+$0.05	-$0.05	$15.60 million	$15.67 million
3/7/2024	Q4 2023	ONC Oncolytics Biotech	-C$0.15	-C$0.05	+C$0.10	-C$0.05	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MXCT MaxCyte	N/A	N/A	N/A	N/A	N/A
ONC Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MXCT MaxCyte	N/A	10.65	9.97
ONC Oncolytics Biotech	1.54	9.01	8.86

Ownership

Institutional Ownership

Company	Institutional Ownership
MXCT MaxCyte	68.81%
ONC Oncolytics Biotech	6.98%

Insider Ownership

Company	Insider Ownership
MXCT MaxCyte	6.00%
ONC Oncolytics Biotech	6.24%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
MXCT MaxCyte	143	104.40 million	98.13 million	Optionable
ONC Oncolytics Biotech	29	75.42 million	N/A	Not Optionable

YGEN, BD1, MXCT, OSL, and ONC Headlines

Source	Headline
	Outrun Therapeutics announces launch with $10m seed funding pharmaceutical-technology.com - April 18 at 7:38 AM
	Biotech expansion for Japanese firm in Holly Springs driven by talent pool, universities carolinapublicpress.org - April 17 at 10:38 AM
	Stocks in play: Oncolytics Biotech® Inc. ca.finance.yahoo.com - April 11 at 3:56 PM
	Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA finance.yahoo.com - April 11 at 8:38 AM
	Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 markets.businessinsider.com - April 10 at 6:01 PM
	Oncolytics Biotech is undervalued, Raymond James says cantechletter.com - April 5 at 3:37 PM
	Oncolytics Biotech (TSE:ONC) Trading Up 10.7% marketbeat.com - April 4 at 10:46 AM
	Closing Bell: Oncolytics Bio down on Friday (ONC) theglobeandmail.com - March 16 at 10:14 AM
	Futures Retreat Sharply msn.com - March 11 at 4:05 PM
	Oncolytics Biotech Inc.: Oncolytics Biotech Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN finanznachrichten.de - March 6 at 4:39 PM
	Econ Corp Services DBA Investorideas.com: Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning finanznachrichten.de - March 6 at 4:39 PM
	A Preview Of Oncolytics Biotech's Earnings benzinga.com - March 6 at 4:39 PM
	Oncolytics Biotech Inc ONC morningstar.com - March 2 at 6:22 PM
	Reiterating Buy Rating: Expanding Potential of Pelareorep in Oncolytics Biotech’s Pipeline markets.businessinsider.com - February 15 at 9:24 AM
	Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments finance.yahoo.com - February 15 at 9:24 AM
	Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies theglobeandmail.com - February 14 at 2:36 PM
	USA News Group: Pancreatic Cancer Treatments Poised for Major Advances in 2024 finanznachrichten.de - February 7 at 11:03 AM
	KaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Viruses finance.yahoo.com - January 31 at 8:47 PM
	Oncolytics Biotech Stock (NASDAQ:ONCY), Analyst Ratings, Price Targets, Predictions benzinga.com - January 6 at 3:30 PM
	JonesTrading Keeps Their Hold Rating on TRACON Pharmaceuticals (TCON) markets.businessinsider.com - December 14 at 8:26 AM
	Oncolytics Biotech Inc.: Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS finanznachrichten.de - December 7 at 8:30 AM
	Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep finance.yahoo.com - November 9 at 7:48 AM
	Oncolytics Biotech's Earnings Outlook benzinga.com - November 3 at 6:37 PM
	Oncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2023 Financial Results and Operational Highlights finanznachrichten.de - November 3 at 1:36 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

MaxCyte

NASDAQ:MXCT

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Oncolytics Biotech

TSE:ONC

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial